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Case Report
Acid Maltase Deficiency — Pompe’s Disease
Sajjad Jamil, Shahid Ahmed, Muhammad Tariq
Department of Medicine, Aga Khan University Hospital, Karachi.
Abstract
Mutation in genes encoding for proteins involved in
glycogen synthesis, degradation or regulation results in
various inborn errors of glycogen metabolism. The disorders
that result in abnormal storage of glycogen are known as
glycogen storage diseases (GSD).We report a rare and
interesting case of a young boy who presented with
generalized weakness and reduced muscle bulk since
childhood. He was diagnosed to have acid maltase deficiency,
also known as Pompe's disease, one of the rare types of
glycogen storage disease. The case is presented here in the
form of a case study, including a review of the pertinent
literature on the subject. This case has the potential to be the
first reported case of such a disease from Pakistan (to the best
of our knowledge).
Keywords: Glycogen Storage disease Type II, Pompe's
disease, Acid Maltase deficiency.
Introduction
Pompe's disease, which is also known as acid maltase
deficiency, is a glycogen storage disease type II. It is an
autosomal recessive lysosomal storage disorder characterized
by acid alpha-glucosidase deficiency. This deficiency results
from mutations in the encoding gene (GAA).  Acid alpha-
glucosidase is an enzyme required to hydrolyze lysosomal
glycogen to glucose. Glycogen is the stored form of glucose
and serves as a buffer for glucose needs. It is composed of
long polymers of a 1-4 linked glucose, interrupted by a 1-6
linked branch point every four to ten residues. 
The clinical manifestations are characterized by
progressive skeletal muscle weakness affecting motor and
respiratory functions and is typical for both adult and infantile
forms of Glycogen storage disease type II (GSD II).1
Overall disease frequency was reported as 1 in 40,000
in one study with an incidence of 1 in 38,000 for infantile
GSD II and 1 in 57,000 for adult GSD II.2,3
Case Report
An 18 years old boy presented to the out-clinic in
March 2005 with weight loss and progressively increasing
weakness for the past eleven years. He further complained to
experience episodes of feeling of suffocation and palpitations
on exertion. His family history was significant, with known
similar illnesses in his uncles, aunties and cousins. All of
them died at ages between 20 and 25 years. His family history
was positive for diabetes mellitus. He also gave history of
consanguineous marriages in the family. 
On examination his blood pressure was
110/80mmHg, heart rate was110 per minute regular and
respiratory rate was 22 breaths per minute. His weight and
height were 36.7 kilogram and 165 centimeters, respectively.
His Body Mass Index (BMI) was 13.5. On general
examination he was pale, thin looking with uniformly
decreased muscle mass, however, he was oriented to time,
place and person. His recent and remote memory was also
intact. His jugular venous pressure was raised but there was
no pedal oedema. His abdominal, respiratory and
cardiovascular examinations were unremarkable except a
loud second heart sound was heard at the cardiac apex. On
musculoskeletal examination the muscle bulk was
significantly reduced all over the body, although the power,
tone and deep tendon reflexes were normal. Investigations
revealed normal complete blood count, serum creatinine,
serum electrolytes, calcium, phosphorous and alkaline
phosphatase. His serum aminotransferase levels were mildly
raised and serum aldolase level was elevated to 25.4 U/L
(0.1-7.6), creatine-phospho-kinase (CPK) level was also
raised at 1179 IU/L (males17-176) and lactate dehydrogenase
level (LDH) was 1205 IU/L (males153-548).  The random
blood sugar, thyroid function tests and serum albumin were
normal. His electrocardiogram showed left ventricular
hypertrophy by voltage criteria, as shown in Figure-3,
however echocardiogram revealed normal left ventricular
systolic functions with no significant left ventricular
hypertrophy. The Chest X-Ray was normal except showing
scoliotic deformity of dorsal spine, whereas X-Ray of the
hands revealed bone age of 18 years but there was no
evidence of rickets. In order to rule out muscular dystrophy,
EMG/NC (electromyography/nerve conduction) study was
done, which showed diffuse irritable myopathic process
consistent with muscle dystrophy. Muscle biopsy was
suggested. The muscle biopsy was taken from the left biceps
and the findings were consistent with Glycogen storage
disease type II (Figure-1,2)
Discussion
Pompe's disease is an autosomal recessive disorder
characterized by deficiency of acid alpha-glucosidase
resulting in intra-lysosomal accumulation of glycogen and
leading to progressive muscle dysfunction. The natural history
of infantile-onset Pompe disease is characterized by
Hypertrophic cardiomyopathy and profound generalized
weakness presenting in the first few months of life, with rapid
progression and death usually occurring by one year of age.
Late-onset Pompe's disease is characterized by onset of
symptoms after one year of age, less severe or absence of
cardiac involvement and slower progression, with symptoms
primarily related to progressive dysfunction of skeletal
muscles and respiratory muscle involvement.4 Our patient had
a late onset disease as he presented at the age of 18 years with
an 11 years history of progressive skeletal muscle weakness,
however there was no significant respiratory muscle
involvement. Recent clinical trials of enzyme replacement
therapy have begun to allow greater opportunity for potential
improvement in motor status, function, and survival than ever
before, with hopes of moving toward maximizing physical
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Figure=1: On H&E multiple bundles of skeletal muscle fibers are seen exhibiting
extensive vacuolization.
Figure-2: On GOMORI trichrome mild increase in fibrosis is noticed and special
stains for glycogen (PAS) are strongly positive.
Figure-3:Electrocardiogram showing large voltage left Ventricular QRS complexes.
function for individuals with Pompe's disease. Children
generally live longer, with some achieving independent
sitting, creeping, and walking-milestones typically never
achieved in the untreated natural history of the disorder.4
Electrocardiogram (ECG) abnormalities are universal
in infantile Pompe's disease. Hallmarks of this disease include
a shortened PR interval, an increased QT dispersion (QTd),
and large left ventricular (LV) voltages, as seen in Figure-3.5
Our patient had increased left ventricular voltage on
electrocardiography; however his echocardiogram did not
show evidence of left ventricular hypertrophy. Adult-onset
glycogen storage disease type II (GSD II) is a progressive
disabling myopathy. At present there is no treatment of
proven clinical efficacy. Enzyme replacement therapy may in
the future provide benefit but it will be costly and is not yet
freely available.6 There is some data which supports that a
high-protein diet may be helpful in adult-onset disease.7,8
In both childhood and adult cases that progress to
respiratory failure, mechanical ventilation is usually
necessary. Noninvasive ventilation during sleep may improve
nighttime hypoxaemia and daytime hypercapnia in some
adult-onset patients.9
Conclusion
Pompe's disease is an extremely rare, inherited
disorder of glycogen metabolism. It causes
progressive muscle weakness leading to death either
because of respiratory or cardiac muscle involvement.
We report the first case (to the best of our knowledge)
of late onset glycogen storage disease type II from
Pakistan.
References
1. Kroos MA, Pomponio RJ, Hagemans ML, Keulemans JL. Broad spectrum of
Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology
2007; 68: 110-5.
2. Ausems MG, Verbiest J, Hermans MP. Frequency of glycogen storage disease
type II in The Netherlands: implications for diagnosis and genetic counselling.
Eur J Hum Genet 1999; 7: 713-7.
3. Martiniuk F, Mehler M, Zall S. Sequence of the cDNA and 5'-flanking region
for human acid alpha-glucosidase, detection of an intron in the 5'
untranslated leader sequence, definition of the 18-bp polymorphisms, and
differences with previous cDNA and amino acid sequence. DNA Cell Biol
1990; 9: 85-8.
4. Case LE, Kishnani PS.  Physical therapy management of Pompe disease. Genet
Med 2006; 8: 318-27.
5. Ansong AK, Li JS, Nozyk-Grayck.  Electrocardiographic response to enzyme
replacement therapy for Pompe disease. Genet Med 2006; 8: 297-301.
6. Mundy HR, Williams JE. The effect of L-alanine therapy in a patient with adult
onset glycogen storage disease type II. J Inherit Metab Dis 2006; 29: 226-9.
7. Margolis ML, Hill AR. Acid maltase deficiency in an adult. Evidence for
improvement in respiratory function with high-protein dietary therapy. Am Rev
Respir Dis 1986; 134: 328.
8. Slonim A, Coleman R, McElligot M.  Improvement of muscle function in acid
maltase deficiency by high-protein therapy. Neurology 1983; 33: 34-8.
9. Mellies U, Stehling F, Dohna-Schwake C. Respiratory failure in Pompe disease:
Treatment with noninvasive ventilation. Neurology 2005; 64: 1465-7.
823 J Pak Med Assoc
